Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.68 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.68 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16592137 | 1.00 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNA7ALDH1A1KCNH2 | |
| SCHEMBL9041158 | 0.83 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL9849965 | 0.79 | CHRNA7 (0.71) | CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL25658 | 0.79 | CHRNA7 (0.71) | CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6154466 | 0.77 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL2340043 | 0.67 | KCNH2 (0.49) | ALDH1A1KCNH2 | |
| SCHEMBL160708 | 0.66 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL21307962 | 0.66 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL29484643 | 0.66 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL19807403 | 0.64 | KCNH2 (0.46) | CHRNB2CHRNA4ALDH1A1KCNH2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009489-A1 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIAN PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-7268232-B2 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-11 | — | — | US | disclosed |
| WO-2007092391-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF TREATING DISEASE USING THE SAME | ACADIA PHARMACEUTICALS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1756101-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | Acadia Pharmaceuticals Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005115361-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIA PHARMACEUTICALS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | NR5A1, AR, CYP17A1 | CHRNB2 2541/4885CHRNA4 3344/4885CHRNA7 2707/4885 |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | NR5A1, AR, ESRRA | CHRNB2 2544/4885CHRNA4 3376/4885CHRNA7 2855/4885 |
| US-20080009489-A1 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | NR5A1, AR, CYP17A1 | CHRNB2 2541/4885CHRNA4 3344/4885CHRNA7 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.